Attached files

file filename
EX-21 - EX-21 - Cardiff Oncology, Inc.a15-1864_1ex21.htm
EX-10.7 - EX-10.7 - Cardiff Oncology, Inc.a15-1864_1ex10d7.htm
EX-23.1 - EX-23.1 - Cardiff Oncology, Inc.a15-1864_1ex23d1.htm
EX-31.1 - EX-31.1 - Cardiff Oncology, Inc.a15-1864_1ex31d1.htm
EX-31.2 - EX-31.2 - Cardiff Oncology, Inc.a15-1864_1ex31d2.htm
EX-10.8 - EX-10.8 - Cardiff Oncology, Inc.a15-1864_1ex10d8.htm
EX-10.6 - EX-10.6 - Cardiff Oncology, Inc.a15-1864_1ex10d6.htm
EX-32.1 - EX-32.1 - Cardiff Oncology, Inc.a15-1864_1ex32d1.htm
EXCEL - IDEA: XBRL DOCUMENT - Cardiff Oncology, Inc.Financial_Report.xls
10-K - 10-K - Cardiff Oncology, Inc.a15-1864_110k.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Trovagene, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen Zaniboni, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

 

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

March 12, 2015

/s/ Stephen Zaniboni

 

 

 

Stephen Zaniboni

 

Chief Financial Officer